JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

145.91

-0.57%↓

Home・Akcijų sąrašas・Cassava Sciences Inc

Cassava Sciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.6 -5.01

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.6

Max

3.74

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-21M -44M
Pelno marža	-2,258.347
Darbuotojai	30
EBITDA	-21M -45M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+110.53% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	104M 213M
Ankstesnė atidarymo kaina	8.61
Ankstesnė uždarymo kaina	3.6

Naujienos nuotaikos

By Acuity

50%

154 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

1.56 / 1.7 Palaikymas ir pasipriešinimas

Cassava Sciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-28 23:50; UTC

Karštos akcijos

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

2025-10-28 23:25; UTC

Uždarbis

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

2025-10-28 23:18; UTC

Uždarbis

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

2025-10-28 22:20; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

2025-10-28 22:13; UTC

Uždarbis

Wal-Mart de Mexico Net Profit Falls in 3Q

2025-10-28 21:38; UTC

Uždarbis

Correction to Visa Sales Jump Article

2025-10-28 21:17; UTC

Uždarbis

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

2025-10-28 21:07; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- Update

2025-10-28 21:02; UTC

Uždarbis

Mondelez Tempers Outlook as Costs Rise

2025-10-28 23:51; UTC

Rinkos pokalbiai

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

2025-10-28 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

2025-10-28 23:02; UTC

Uždarbis

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

2025-10-28 23:01; UTC

Uždarbis

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

2025-10-28 22:46; UTC

Uždarbis

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

2025-10-28 22:45; UTC

Uždarbis

SK Hynix 3Q Net KRW12.6T >000660.SE

2025-10-28 22:44; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.44T >000660.SE

2025-10-28 22:43; UTC

Uždarbis

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

2025-10-28 22:42; UTC

Uždarbis

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

2025-10-28 22:20; UTC

Uždarbis

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

2025-10-28 22:02; UTC

Uždarbis

Review & Preview: Earnings Extravaganza -- Barrons.com

2025-10-28 21:42; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2025-10-28 21:42; UTC

Rinkos pokalbiai

Uždarbis

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

2025-10-28 21:20; UTC

Uždarbis

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

2025-10-28 21:19; UTC

Uždarbis

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

2025-10-28 21:18; UTC

Uždarbis

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Akcijų palyginimas

Kainos pokytis

Cassava Sciences Inc Prognozė

Kainos tikslas

By TipRanks

110.53% į viršų

12 mėnesių prognozė

Vidutinis 8 USD 110.53%

Aukščiausias 8 USD

Žemiausias 8 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cassava Sciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Cassava Sciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.56 / 1.7Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

154 / 373 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.